Do you want to read an article? Please log in or register.
Treatment patterns and persistence rates with anti-VEGF treatment for diabetic macular edema in the UK: a real-world study
Further Publications
Related content
Diabetes - GeneralType 2 Diabetes
PERS&O (PERsistent Sitagliptin treatment & Outcomes): observational retrospective study on cardiovascular risk evolution in patients with type 2 diabetes on persistent sitagliptin treatment
BMJ Open Diabetes Res Care.
Buonaiuto G, De Mori V, Braus A, Balini A, Berzi D, Carpinteri R, Forloni F, Meregalli G, Ronco GL, Bossi AC
doi: 10.1136/bmjdrc-2016-000216.
Lipids
Patient Characteristics and Real-World Treatment Patterns Among Early Users of PCSK9 Inhibitors
Am J Cardiovasc Drugs.
Rane PB, Patel J, Harrison DJ, Shepherd J, Leith A, Bailey H, Piercy J
doi: 10.1007/s40256-017-0246-z.
Diabetes - GeneralType 2 DiabetesGlycemic Control
Long-term sustainability of glycaemic achievements with second-line anti-diabetic therapies in patients with type 2 diabetes: A real-world study
Diabetes Obes Metab.
Montvida O, Shaw J, Blonde L, Paul SK
doi: 10.1111/dom.13288.
Diabetic Complications
A Review of Ranibizumab for the Treatment of Diabetic Retinopathy
Ophthalmol Ther.
Stewart MW
doi: 10.1007/s40123-017-0083-9.
Diabetes - GeneralType 2 DiabetesDiabetic Complications
Association of Diabetic Macular Edema and Proliferative Diabetic Retinopathy With Cardiovascular Disease: A Systematic Review and Meta-analysis
JAMA Ophthalmol
Xie J, Ikram MK, Cotch MF, Klein B, Varma R, Shaw JE, Klein R, Mitchell P, Lamoureux EL, Wong TY
COMMENTED
Type 2 Diabetes
Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study
★ 2
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
Lancet Diabetes Endocrinol.
Heerspink HJL, Karasik A, Thuresson M, Melzer-Cohen C, Chodick G, Khunti K, Wilding JPH, Garcia Rodriguez LA, Cea-Soriano L, Kohsaka S, Nicolucci A, Lucisano G, Lin FJ, Wang CY, Wittbrodt E, Fenici P, Kosiborod M
doi: 10.1016/S2213-8587(19)30384-5.
Type 2 Diabetes
Cardiovascular risk profiles: A cross-sectional study evaluating the generalisability of the glucagon-like peptide-1 receptor agonist cardiovascular outcome trials Rewind, Leader and Sustain-6 to the real-world type 2 diabetes population in the UK
Diabetes Obes Metab
Webb J, Mount J, von Arx LB, Rachman J, Spanopoulos D, Wood R, Tritton T, Massey O, Idris I
doi: 10.1111/dom.14580
Type 2 DiabetesDiabetic ComplicationsGlycemic Control
Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study.
Diabetes Care.
Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Eye Study Group and the Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Study Group
doi: 10.2337/dc16-0024.
Diabetes - General
Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA)
Ophthalmologica.
Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, Berg K, Chakravarthy U, Gerendas BS, Jonas J, Larsen M, Tadayoni R, Loewenstein A
doi: 10.1159/000458539.